Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry.
about
Rationale for full-season dosing for passive antibody prophylaxis of respiratory syncytial virusDefining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Infants with Chronic Lung DiseaseConsensus conference on the appropriateness of palivizumab prophylaxis in respiratory syncytial virus disease.Outcomes of palivizumab prophylaxis for respiratory syncytial virus infection in preterm children with bronchopulmonary dysplasia at a single hospital in Korea from 2005 to 2009.A novel six consecutive monthly doses of palivizumab prophylaxis protocol for the prevention of respiratory syncytial virus infection in high-risk preterm infants in Taiwan.Respiratory Syncytial Virus Infection in High-risk Infants - an Update on Palivizumab ProphylaxisPalivizumab compliance by infants in Puerto Rico during the 2009-2010 respiratory syncytial virus season.Safety and Effectiveness of Palivizumab in Children at High Risk of Serious Disease Due to Respiratory Syncytial Virus Infection: A Systematic Review.Association of RSV-related hospitalization and non-compliance with palivizumab among commercially insured infants: a retrospective claims analysis.Partial palivizumab prophylaxis and increased risk of hospitalization due to respiratory syncytial virus in a Medicaid population: a retrospective cohort analysis.A decade of respiratory syncytial virus epidemiology and prophylaxis: translating evidence into everyday clinical practice.Respiratory syncytial virus hospitalization trends in infants with chronic lung disease of infancy, 1998-2008Effect of Prophylactic Palivizumab on Admission Due to Respiratory Syncytial Virus Infection in Former Very Low Birth Weight Infants with Bronchopulmonary Dysplasia.Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populationsTrends in Respiratory Syncytial Virus and Bronchiolitis Hospitalization Rates in High-Risk Infants in a United States Nationally Representative Database, 1997-2012.A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS).Clinical Decision Support and Palivizumab: A Means to Protect from Respiratory Syncytial VirusReview of the home care programmes for respiratory syncytial virus (RSV) prophylaxis in Ireland and The NetherlandsRespiratory-related hospitalizations following prophylaxis in the Canadian registry for palivizumab (2005-2012) compared to other international registriesFirst versus second year respiratory syncytial virus prophylaxis in chronic lung disease (2005-2015).Respiratory Syncytial Virus Infection Rates with Limited Use of Palivizumab for Infants Born at 29 to 31+6/7 Weeks Gestational Age.Prevention of serious respiratory syncytial virus-related illness. II: Immunoprophylaxis.Does prophylaxis with palivizumab reduce hospitalisation rates for respiratory-syncytial-virus-related infection in cystic fibrosis children less than 2 years of age?Risk of respiratory syncytial virus infection in preterm infants: reviewing the need for prevention.Immunotherapy for infectious diseases in haematological immunocompromise.Incidence of Respiratory Disease During the First Two Years of Life in Children with Hemodynamically Significant Congenital Heart Disease in Italy: A Retrospective Study.Effectiveness of palivizumab in children with childhood interstitial lung disease: The French experience.Insurance Status and the Risk of Severe Respiratory Syncytial Virus Disease in United States Preterm Infants Born at 32-35 Weeks Gestational Age.Value of a risk scoring tool to predict respiratory syncytial virus disease severity and need for hospitalization in term infants.Improving Palivizumab Compliance rough a Pharmacist-Managed RSV Prevention ClinicRespiratory syncytial virus immunoprophylaxis in high-risk infants with heart disease.Adherence and outcomes: a systematic review of palivizumab utilization.RI-002, an intravenous immunoglobulin containing high titer neutralizing antibody to RSV and other respiratory viruses for use in primary immunodeficiency disease and other immune compromised populations.Assessing Variation in the Cost of Palivizumab for Respiratory Syncytial Virus Prevention in Preterm Infants.Past, Present and Future Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children.Letters to the Editor.Initial Palivizumab Dose Administration in Outpatient Clinic After Hospital Discharge.Effectiveness of palivizumab prophylaxis in infants and children in Florida
P2860
Q26825438-CFAE5D51-553B-484A-BE96-8708C743F3E1Q28067464-AD076BD3-6130-4684-8A1F-EBF892FE7B05Q30245434-F34FAA42-4AA9-463A-BFAB-0FA76D9EC299Q33610003-99F56A29-F485-4FF0-8F2C-FF70A39F1AD4Q33817471-35C0E2B3-0519-4886-849F-21C127D6122DQ34049590-56D70AD4-1036-4A1E-B1BE-60424C43D4E3Q34446682-4472D74F-F4B4-4516-ACD9-EDBBCB9DB751Q34726169-5463C4F8-1F09-439D-861A-9393E32F5111Q34839654-6F2AC3B1-4A02-4337-B536-D6F7D9BE8D32Q34875961-1FC3CD16-DE94-4153-8E0D-5B7FFA4D3C06Q34884984-810BBB7B-0688-459F-BAB1-B3A35917D3E9Q35315447-E6BF9A9C-0693-4677-BF92-43A6270ECC25Q35778606-34FDEA84-AC7A-4A21-A9F3-81EC1DBE4A22Q35892685-32800F83-8D88-4FE6-993A-166E3E2EEAD3Q35980935-45C443F5-C0EB-4EB3-A1C9-5524336B6161Q36275397-D5DA0C7E-03F8-417B-94A6-CD8462CF459FQ36438581-2B47B91D-99EC-4CD5-BD45-878F5285E0D6Q36582250-541DD5C4-AFDD-4848-ADF2-4EF1B8C2B7B8Q36989863-A7053711-2F67-446A-A500-0BD16E7221A0Q37660572-A0EE7EF3-E212-45FF-A71F-82F958C07044Q37711133-529DD702-95D1-4A23-902B-95DE625D7F61Q37841264-C345B3D8-DC1A-4459-86F1-E592CD6F9DCAQ38057771-30CE6557-79AB-4B00-9406-4898942C0634Q38604949-3F7BB242-3A12-4948-BAC8-7B6FBCF3BA5DQ39215653-BCD85FFD-724D-4F78-AF6C-4E0014DE1E4BQ39442518-EDB30ED7-8BC6-43C6-A91C-837081DB05CEQ40242543-76E779EC-DFC0-4CD0-9A10-CC8FD6FA4ECFQ40516621-ABDD431C-6611-417E-AB71-5542AE0DDC84Q41199983-D0C2679D-3844-4B4B-833B-7FE3A9602C37Q42376924-091A64BF-BE0A-48EA-A4F5-44F3D2F560F3Q45356671-A5BF4542-E23A-46E3-A74E-287DB9BA600DQ47582466-5D998AA1-D5CA-43F0-BC41-EDC7059BFFE0Q47611490-6941F984-65AC-4E6C-9E93-6F521E413FA7Q49720574-036A52A0-3266-434E-989B-337AFA676E65Q50262223-7740670C-C877-49A6-975F-8C86B6F8D155Q51558042-7ECDDE62-669D-4B2F-8747-6CF19412DC16Q52640514-F82EFC88-56D8-4473-8813-7EA279B8F823Q57830092-360E2736-51D3-4C38-9225-BB656FE9F178
P2860
Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Prevention of hospitalization ...... Palivizumab Outcomes Registry.
@en
Prevention of hospitalization ...... Palivizumab Outcomes Registry.
@nl
type
label
Prevention of hospitalization ...... Palivizumab Outcomes Registry.
@en
Prevention of hospitalization ...... Palivizumab Outcomes Registry.
@nl
prefLabel
Prevention of hospitalization ...... Palivizumab Outcomes Registry.
@en
Prevention of hospitalization ...... Palivizumab Outcomes Registry.
@nl
P2093
P2860
P356
P1476
Prevention of hospitalization ...... Palivizumab Outcomes Registry.
@en
P2093
M Harrington
P VanVeldhuisen
Palivizumab Outcomes Registry Group
P2860
P2888
P304
P356
10.1038/JP.2008.28
P577
2008-03-27T00:00:00Z
P5875
P6179
1025398396